Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SPRO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| TBP-PI-HBr | Urinary Tract Infection | Phase 3 · NCT06059846 | Completed |
| Dummy Infusion | Urinary Tract Infection | Phase 3 · NCT06059846 | Completed |
| TBPM-PI-HBr | Complicated Urinary Tract Infection | Phase 3 · NCT03788967 | Completed |
| Imipenem-cilastatin | Urinary Tract Infection | Phase 3 · NCT06059846 | Completed |
| SPR720 | Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) | Phase 2 · NCT05496374 | Completed |
| Tebipenem Pivoxil Hydrobromide | Diabetes | Phase 1 · NCT04919954 | Completed |
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)… | Healthy Volunteers | Phase 1 · NCT04421885 | Completed |
| SPR994 | Healthy Volunteers | Phase 1 · NCT03395249 | Completed |
| SPR741 | Healthy Volunteers | Phase 1 · NCT03376529 | Completed |
| SPR720 for SAD | Healthy Volunteers | Phase 1 · NCT03796910 | Completed |
| Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)… | Healthy Volunteers | Phase 1 · NCT04421885 | Completed |
| Tebipenem tablet form | Relative Bioavailability | Phase 1 · NCT05296382 | Completed |
| SPR206 | Renal Impairment | Phase 1 · NCT04865393 | Completed |
| SPR720 for MAD | Healthy Volunteers | Phase 1 · NCT03796910 | Completed |
| Orapenem® | Healthy Volunteers | Phase 1 · NCT03395249 | Completed |
| Moxifloxacin | TQT Study | Phase 1 · NCT04238195 | Completed |
Also used in these trials (approved or third-party drugs, not SPRO's own candidates): Ertapenem Sodium, Piperacillin Sodium, Tazobactam Sodium, Omeprazole, Ceftazidime, Aztreonam, Azithromycin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SPRO holds $107.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $24M/quarter from operations, an estimated runway of 13.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 28 · Moderate
Based on our current operating plan, we believe that our cash and cash equivalents as of September 30, 2026 will be sufficient to fund our operating expenses and capital expenditure requirements into the second half of 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SPRO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| GSK PLC | Institution (13G, 5%+) | 9,190,606 | 15.77% | 2025-03-27 |
| Pfizer Inc | Institution (13F) | 2,362,348 | 4.05% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 2,036,226 | 3.49% | 2026-09-30 |
| Mackenzie Financial Corporation | Institution (13F) | 1,831,254 | 3.14% | 2026-09-30 |
| Sath Shukla CEO & President |
Insider | 1,736,883 | 2.98% | 2025-02-03 |
| Renaissance Technologies, LLC | Institution (13F) | 1,409,783 | 2.42% | 2026-09-30 |
| Affinity Asset Advisors, Llc | Institution (13F) | 1,300,000 | 2.23% | 2026-09-30 |
| Arrowstreet Capital, Limited Partnership | Institution (13F) | 997,123 | 1.71% | 2026-09-30 |
| Esther Rajavelu Chief Executive Officer and Chief Financ · +498,000 options |
Insider | 946,000 | 1.62% | 2026-11-06 |
| Verdad Advisers, LP | Institution (13F) | 805,702 | 1.38% | 2026-09-30 |
| Raymond James Financial, Inc. | Institution (13F) | 755,633 | 1.30% | 2026-09-30 |
| Timothy Keutzer Chief Operating Officer |
Insider | 742,506 | 1.27% | 2026-02-06 |
Share count 58,264,577 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-10 filed 2026-11-10 |
HO WILLIAM |
Option award (A) | 100,000 | – | – |
| 2026-11-09 filed 2026-11-10 |
Rajavelu Esther |
Sale (S) | 40,851 | $1.04 | 946,000 |
| 2026-08-03 filed 2026-08-06 |
Zack Debra |
Award (A) | 162,311 | – | 162,311 |
| 2026-08-03 filed 2026-08-06 |
Zack Debra |
Option award (A) | 324,675 | – | – |
| 2026-06-23 filed 2026-06-25 |
Smith Cynthia |
Option award (A) | 20,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-06-18 | Utebzi | NDA | -18.2% | +8.1% | -4.3% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPRO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →